Altamira Therapeutics Ltd

Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through the following geographical segments: United States, Switzerland, Europe, and Australia. Its product pipeline includes AM-125, AM-201, AM301, Sonsuvi, and Keyzilen. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through the Switzerland and Australia geographical segments. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

HAMILTON, BERMUDA , Jan. 08, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit

Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit

HAMILTON, BERMUDA, Dec. 29, 2023 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA, Dec. 29, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, announced that it received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") on December 28, 2023, indicating that the Company has regained compliance with the minimum bid price requirement. As a result, the listing matter has been closed.

Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Altamira Therapeutics Ltd. (NASDAQ:CYTO ) Special Call December 11, 2023 8:30 AM ET Company Participants Thomas Meyer - Founder, Chairman and CEO Conference Call Participants Operator Good morning, and welcome to Altamira Therapeutics December 23, 2023 Investor Business Update Conference Call.

Altamira Therapeutics Ltd. (CYTO) Special Call Transcript

HAMILTON, BERMUDA , Dec. 05, 2023 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA--December 5, 2023--Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced today that it will host an Investor and Business Update Call on Monday, December 11, 2023, 8:30 a.m. ET. The presentation will be available via teleconference or webcast with audio and presenter-controlled slides.

Altamira Therapeutics to Host Investor & Business Update Call on December 11th

Apple

AbbVie

AMC Entertainment

Amazon

Salesforce

Disney

GameStop

Unlimited HFND Multi-Strategy Return Tracker ETF

ImmunoGen

Microsoft

Nutanix

NVIDIA

Pure Storage

RedHill Biopharma

Snowflake

Tesla

Ulta Beauty

Stocks are poised for an upbeat finish to the best month of gains for 2023, as the fever pitch around Fed rate cuts next year grows. It's all teeing up nicely for that Santa rally, maybe.

These advisers say markets are expecting unrealistic outcomes. Here are some alternatives.

- Partial spin-off of Bentrio® completed to increase focus on RNA delivery activities - Retains 49% in Altamira Medica AG, and secures 25% of future licensing revenue HAMILTON, BERMUDA, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it recently received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”), informing the Company that it has regained compliance with the minimum stockholders' equity requirement as set forth under Nasdaq Listing Rule 5550(b)(1) for continued listing on Nasdaq.

Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement

Altamira Therapeutics (NASDAQ: CYTO ) stock isn't doing so hot on Monday after the company was given a delisting notice last week. That delisting notice comes from the Listing Qualifications Department of the Nasdaq Exchange.

Why Is Altamira Therapeutics (CYTO) Stock Down 8% Today?

Fortress Biotech

Hookipa Pharma Inc

Kronos Bio

Whether you're looking at the “ Magnificent Seven stocks ,” or just the next round of penny stocks to watch, news & company events can quickly sway sentiment. This week is a short holiday week with Thursday's Thanksgiving Holiday and one of the “Magnificent Seven” could become a major catalyst.

Best Penny Stocks To Buy This Week? 4 To Watch Now

Among the leading gainers in the market today, Altamira Therapeutics (NASDAQ: CYTO ) is certainly raising eyebrows. In earlier trading, shares of the biotech company focused on RNA-based therapeutics more than tripled.

Why Is Altamira Therapeutics (CYTO) Stock Up 160% Today?

Ardelyx

Heron Therapeutics

LumiraDx Ltd

When it comes to finding penny stocks to buy, there are plenty of things you'll need to make note of. Sure, broader stock market news trends don't directly influence cheap stocks.

Penny Stocks To Buy? 4 Under $5 To Watch Right Now

Initiates Strategic Repositioning to Focus on Company's Core RNA Delivery Technology Altamira Therapeutics retains 49% in Altamira Medica AG, and secures 25% of future licensing revenue Hamilton, Bermuda, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it has entered into a binding agreement for the sale of a 51% stake in its subsidiary Altamira Medica AG (“Medica”) to a Swiss private equity investor as part of its strategic repositioning around its RNA delivery technology.

Altamira Therapeutics Announces Partial Spin-Off of Bentrio® Business

Hamilton, Bermuda, Nov. 10, 2023 (GLOBE NEWSWIRE) -- November 10, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that it has received an “Intention to Grant” notice from the European Patent Office (EPO) for its patent application titled “Intranasal Composition Comprising Betahistine” (designated as European Patent 3698791).

Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine

Altamira Therapeutics (NASDAQ: CYTO ) stock is rising higher on Friday despite a lack of news from the biopharmaceutical company. There are no new press releases or filings with the Securities and Exchange Commission (SEC) that explain why the stock is up today.

Why Is Altamira Therapeutics (CYTO) Stock Up 28% Today?

HAMILTON, BERMUDA , Sept. 14, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced further positive and statistically significant efficacy data from the randomized controlled NASAR clinical trial, which evaluated their Bentrio nasal spray in seasonal allergic rhinitis (SAR). Bentrio nasal spray is formulated as a drug-free and preservative-free gel emulsion designed to help protect against airborne allergens such as pollen or house dust mites.

Altamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis

Altamira Therapeutics Ltd. (NASDAQ:CYTO ) Q2 2023 Earnings Conference Call September 12, 2023 8:00 AM ET Company Participants Thomas Meyer - Founder, Chairman & CEO Covadonga Paneda - Chief Operating Officer Conference Call Participants Operator Good morning, and welcome to the Altamira Therapeutics First Half 2023 Financial Results and Business Update Conference Call.

Altamira Therapeutics Ltd. (CYTO) Q2 2023 Earnings Call Transcript

HAMILTON, BERMUDA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ:CYTO) ("Altamira" or the "Company"), a company dedicated to addressing unmet medical needs, today provided a business update and reported its first half 2023 financial results.

Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results

HAMILTON, BERMUDA , Sept. 06, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced that it will host its First Half of 2023 Financial Results and Business Update Call on Tuesday, September 12, 2023. Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will deliver prepared remarks followed by a Q&A session where they will address questions from investors and analysts.

Altamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12th

HAMILTON, BERMUDA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its founder, Chairman, and CEO Thomas Meyer will be presenting at the H.C. Wainwright 25th Annual Global Investment Conference, being held virtually and in person on September 11-13, 2023, at Lotte New York Palace Hotel in New York City.

Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13

HAMILTON, BERMUDA, July 20, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced today that it has entered into an exclusive agreement with Pharma Nordic AS for the marketing and distribution of Bentrio®, a nasal spray for protection against airborne allergens, in Norway and potentially further Scandinavian countries. The collaboration agreement will allow Pharma Nordic to market and commercialize Bentrio in Norway beginning in the first quarter of 2024, and, subject to meeting certain milestones, also in Sweden, Finland, and Denmark later on.

Altamira Therapeutics and Pharma Nordic Collaborate for Marketing and Distribution of Bentrio in Scandinavia

HAMILTON, BERMUDA, July 17, 2023 (GLOBE NEWSWIRE) -- -Detailed results from house dust mite trial published in Clinical and Translational Allergy -Study demonstrates statistically significant alleviation of nasal symptoms of allergic rhinitis

Altamira Therapeutics Announces Publication of Positive Results from Clinical Trial with Bentrio in House Dust Mite Allergy in Leading Peer Reviewed Journal

HAMILTON, BERMUDA / ACCESSWIRE / July 6, 2023 / Altamira Therapeutics Ltd. ("Company") (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, announced today the pricing of a public offering of 11,111,112 common shares (or pre-funded warrants in lieu thereof) accompanied by common warrants to purchase up to 11,111,112 common shares, at a combined public offering price of $0.45 per share (or pre-funded warrant in lieu thereof) and accompanying common warrant.

Altamira Therapeutics Announces Pricing of $5.0 Million Public Offering

HAMILTON, BERMUDA , July 05, 2023 (GLOBE NEWSWIRE) -- Heqet will test nanoparticles based on Altamira's OligoPhore delivery platform in the regeneration of damaged heart tissue

Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac Regeneration

HAMILTON, BERMUDA / ACCESSWIRE / June 15, 2023 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that the U.S. Food and Drug Administration ("FDA") has completed its safety review of the Company's Investigational New Drug (IND) application for AM-125 (betahistine nasal spray) in acute vestibular syndrome (AVS).

Altamira Therapeutics Announces IND Clearance by U.S. FDA for AM-125 in Acute Vestibular Syndrome

HAMILTON, BERMUDA / ACCESSWIRE / May 31, 2023 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced the publication of a peer-reviewed article in the International Journal of Molecular Sciences (IJMS) reviewing the challenges in the safe and effective delivery of RNA molecules to target cells beyond the liver.

Altamira Therapeutics Announces Publication of Peer-Reviewed Article on Peptide-Based RNA Delivery for Extrahepatic Targets

Getaround Inc

Minerva Surgical

If you're looking for the best penny stocks to buy today, you should be well-prepared to deal with high volatility. Whether it's the latest debt ceiling crisis, pandemic fear reemerging, today's Fed meeting minutes from May, or speeches by Janet Yellen and Federal Reserve members, there are plenty of headlines to contend with.

News for Altamira Therapeutics Ltd Stock (CYTO)